In drug development, biotechnology refers to the use of biological systems, particularly cells, microorganisms or biological starting materials, to produce and study active substances. It is an umbrella term for manufacturing and development approaches involving biotechnological or biological medicinal products. Key features include control of biological starting systems, purification of complex molecules and their comprehensive analytical characterization.
Biotechnological medicinal products and cell lines
Biotechnological manufacturing processes are used, among other things, for proteins, polypeptides and their derivatives. In suitable expression systems, bacterial, yeast, insect, plant or mammalian cells produce the desired active substance. For many products, the quality strategy begins with the selection, establishment and characterization of a cell line and the creation of cell banks. These starting materials must be controlled throughout the manufacturing period because changes in the biological system may affect the properties of the product.
Manufacturing typically comprises cultivation of the cells and recovery of the produced molecule. This is followed by several purification steps to separate the target product from cell components, host cell proteins, nucleic acids, process residues and undesired product variants. The specific process chain depends on the molecule and the production system. For products derived from cell culture, control of possible microbial or viral contamination is also an essential part of the quality and safety assessment.
Characterization, specifications and comparability
Biotechnologically produced molecules are often structurally complex and may exhibit natural heterogeneity. ICH Q6B therefore requires characterization using suitable methods before specifications are derived. Relevant properties include physicochemical characteristics, biological activity, where applicable immunochemical properties, purity and impurities. For proteins, amino acid sequence, higher-order structure, size, charge variants and post-translational modifications may, for example, be important.
Specifications are not a complete description of a product, but justified testing criteria for ensuring consistent quality. Changes to the cell line, culture conditions, purification or analytical methods may therefore require a comparability assessment. This assessment is intended to demonstrate that the manufacturing change has not adversely altered product characteristics relevant to quality, safety and efficacy. The nonclinical safety assessment of biotechnologically derived medicinal products also takes into account the biological relevance of animal species and the mechanism of action.
Characterization accompanies the development pathway and must not be reduced to a single release test. Analytical methods must be suitable for detecting relevant differences between batches. Findings from characterization justify specifications, support the assessment of process changes and establish the link between the manufactured active substance and the batches investigated in studies.
Distinction from chemical synthesis, gene therapy and established technology
In contrast to classical chemical synthesis, biotechnology focuses on a biological production system. Low-molecular-weight chemical active substances are generally produced through defined chemical reaction steps and controlled using different analytical approaches. The distinction is not based solely on molecular size, but particularly on origin, manufacturing process and quality profile. Biotechnology therefore does not describe a blanket quality advantage, but a specific technical and regulatory context.
Gene therapy is likewise not synonymous with biotechnology. It describes a form of therapy whose intended effect is linked to genetic material or genetic modification. A gene therapy medicinal product may be manufactured biotechnologically, but “biotechnology” also encompasses other products such as recombinant proteins or monoclonal antibodies. “Established technology” is not a synonym either: the term refers to the regulatory and clinical classification of a technology, not merely to the fact that a product is manufactured biologically.
Relevance for clinical trials
The properties of a biotechnological active substance affect its development and clinical testing. Changes to the manufacturing process must be linked to the batches used in nonclinical and clinical studies. Study documents require clear information on the investigational medicinal product, storage, reconstitution and handling. Depending on the product, immunogenicity, infusion-related reactions, stability and batch traceability may require particular attention. A traceable link between manufacturing data and clinical safety monitoring is essential.
Full-service CROs such as Mediconomics support the translation of product-specific requirements into the protocol, investigator’s brochure and operational processes. This includes coordination of medicinal product logistics and temperature monitoring, training of trial sites in handling, collection of product-specific safety data and coordination of monitoring, data management, pharmacovigilance and medical writing. This ensures that manufacturing characteristics and the conduct of the clinical trial remain aligned.
Frequently Asked Questions (FAQ)
Are all biological medicinal products manufactured biotechnologically?
Not necessarily. The term biological medicinal product may encompass various biological products. Biotechnological manufacturing processes refer in particular to controlled cell or expression systems and the active substances obtained from them.
Why is the cell line important for product quality?
The cell line is the biological starting system for many active substances. Its properties may affect product formation, product variants and possible impurities and must therefore be controlled.
Is gene therapy merely a biotechnologically manufactured medicinal product?
No. It is defined by its therapeutic approach involving genetic material. Biotechnological manufacturing may be part of development, but it does not replace this technical classification.
Regulatory references
- ICH Q6B “Specifications” – describes characterization and specifications for biotechnological and biological products.
- ICH S6(R1) “Preclinical Safety Evaluation” – provides the framework for the nonclinical safety assessment of biotechnologically derived medicinal products.
- ICH Q5D – addresses the derivation and characterization of cell substrates for biotechnological products.
- Directive 2001/83/EC, Annex I – contains requirements for marketing authorization applications for medicinal products.